⭐️The future of oncology is bright & these amazing young people are why! Wonderful lunch with the oncology fellows @nyulangone@Perlmutter_CC@nyuniversity with an energizing Q&A on tumor-agnostics, drug development, clinical trials, building a career in oncology, why we need sequencing for all & @ASCO@ConquerCancerFd YIA & much much more…
⭐️Their curiosity+passion, recharged my inner batteries & made me even more excited to work alongside the next generation. We need every one of them here & everywhere, their ideas, talent, & determination, to tackle the emperor of all maladies! #Oncology #Mentorship @OncoAlert@oncodaily@Aiims1742@JohnPLeonardMD
Every treatment available today started as a clinical trial. Let’s Win helps patients and families learn about emerging treatments and trials. https://t.co/w20jDvrqqX #WPCD
We are recruiting for an outstanding clinical/translational leader and physician to serve as Section Chief, Thoracic Medical Oncology - contact me if interested @Perlmutter_CC@nyulangone@nyugrossman https://t.co/7ypBTQ1Bzs
📣 Today #FDA approved giredestrant in combination with everolimus for adults with ER+/HER-/ESR1 mutated #MetastaticBreastCancer after prior endocrine therapy in adjuvant or advanced setting.
More detailed info here: https://t.co/0THbxUE6FU.
#OncTwitter#bcsm#MedTwitter
Clonal evolution. Wheler was here too but she left before the photo. Proud of these mentees and wonderful opportunity to see them at TargetCancer Foundation meeting for rare cancers. 🧨🦄🦓🎯💡👏
Vivek Subbiah Reflects on Five Years of Progress and the Next Frontier in Rare Cancer Precision Oncology at Target Cancer Foundation’s Meeting
@VivekSubbiah@targetcancer
https://t.co/ADyDFQo3wX
🚨Which clinical specialties are shielded from AI, and which are exposed? New @NEJM_AI , the authors measure how much of each specialty's work requires in-person physical interaction and what that means for AI's reach into practice.
👉"Physical Limits to AI Substitution across Physician Specialties- Implications for the Physician Workforce" @NEJM@NEJM_AI@OncoAlert https://t.co/EZQp3igcSK
🚨⭐️Your Outlook email may not be working & your flight may be delayed ✈️ so you might have a few minutes to read our Perspective, just published hot off the press @Nature@Nature_NPJ
👉Open access, free for all to read - at least @X & internet are working :) #precisionmedicine #AI
👉"AI-based prediction of actionable genomic alterations from H&E-stained slides" 🔬
👉Tissue exhaustion & slow turnaround still keep patients from the right targeted therapy. Deep learning models can now predict actionable genomic alterations directly from routine H&E, and the prospective EAGLE (EGFR, NSCLC) and ANNAR (FGFR, urothelial) studies show this holds across diverse global cohorts.
👉Near-instant, non-destructive results let us triage patients for molecular testing or clinical trials at the time of diagnosis. Every lab in the world makes an H&E slide, and this puts molecular information within reach of all of them @OncoAlert@oncodaily
https://t.co/PU6tiNatvG
⭐️One of my favorite meetings of the year is today: Target Cancer Foundation's Rare Cancer Precision Oncology meeting. @targetcancer@Dr_R_Kurzrock
⭐️Looking forward to delivering my lecture “AGNOSTIC BY DESIGN: Five Years That Redrew the Map of Rare Cancer Precision Oncology, & the Next Frontier” 🧬🎯🚀@OncoAlert@oncodaily@OncBrothers@OpenMedInsights@OpenMedKate
#TCFTargetcancer2026
#RareCancer #PrecisionOncology
https://t.co/kKlAXsRvc1
The TROP2/NMR/QCS/ paper is out @NatureMedicine 👉Normalized membrane ratio of TROP2 as a predictor of clinical outcomes with datopotamab deruxtecan in non-small-cell lung cancer
👉Scoring TROP2 IHC by eye doesn’t predict who benefits from TROP2 ADCs. Computational pathology does.
✅TROP2 QCS-NMR in TROPION-Lung01, NMR+ vs NMR–
👉Dato-DXd PFS 7.2 vs 4.0 mo (HR 0.40)
👉Docetaxel 4.1 vs 4.4 mo (HR 0.94)
👉An emerging predictive biomarker for Dato-DXd. #LCSM @OncoAlert@oncodaily https://t.co/PafVN9uBWw
Great things happen in pairs!!
National Leader in Cancer Symptom Management, Ishwaria Subbiah, MD, Joins @Perlmutter_CC@nyulangone
Welcome to PCC and New York City @IshwariaMD - we are so excited to have you and your family here.
@JohnPLeonardMD
https://t.co/AJDDLlpVne